US 12,171,753 B2
Crystalline forms of ALDH2 modulators
Lewis Feldberg, Montclair, NJ (US); Akram Sabouni, Cary, NC (US); Thomas R. Bailey, Phoenixville, PA (US); Vincent Wing-Fai Tai, San Diego, CA (US); and Tom Leyssens, Jette (BE)
Assigned to Sophrosyne Pharmaceuticals Limited, George Town (KY)
Filed by SOPHROSYNE PHARMACEUTICALS LIMITED, George Town (KY)
Filed on Jun. 10, 2022, as Appl. No. 17/837,619.
Claims priority of provisional application 63/202,423, filed on Jun. 10, 2021.
Prior Publication US 2023/0096245 A1, Mar. 30, 2023
Int. Cl. A61K 31/44 (2006.01); A61K 45/06 (2006.01); A61P 25/32 (2006.01); C07D 211/60 (2006.01)
CPC A61K 31/44 (2013.01) [A61K 45/06 (2013.01); A61P 25/32 (2018.01); C07D 211/60 (2013.01); C07B 2200/13 (2013.01)] 21 Claims
 
1. A co-crystalline form comprising
a compound having a formula of

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
 and
a coformer, wherein the coformer is urea, 3,5-dihydroxybenzoic acid, trimesic acid, ellagic acid, MgCl2, or CaCl2), or any combination thereof,
wherein
n is 0-6;
m is 0-6; and
p is 0-6.